Bear Stearns Downgrades Momenta Pharmaceuticals (MNTA) to Peer Perform
More News related to MNTA
- FTN Equity Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
- Momenta Pharmaceuticals (MNTA) Dec volatility at 89, March at 121 into FDA
- Oppenheimer Upgrades Momenta Pharmaceuticals (MNTA) to Outperform
- Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
- Canaccord Adams Initiates Coverage on Momenta Pharmaceuticals (MNTA) with a Buy
More News related to Downgrades
- JANCO Partners Downgrades Energy Conversion Devices (ENER) to Sell
- Feltl & Co. Downgrades ArcSight (ARST) to Sell
- Credit Suisse Downgrades Comcast (CMCSA) to Neutral
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
Bear Stearns downgrades Momenta Pharmaceuticals (Nasdaq: MNTA) from Outperform to Peer Perform.
Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. [BCS]
Related Categories
DowngradesStocks Mentioned
+0.24Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
